Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders

Molecules

Volumn 16, Issue 3, 2011, Pages 2097-2106

  Cleva, Richard M ^a   Olive, M Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Addiction; Glutamate; Learning; Memory; Metabotropic; Positive allosteric modulator; Receptor; Schizophrenia; Synaptic plasticity

Indexed keywords

AMINO ACID RECEPTOR AFFECTING AGENT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5;

ALLOSTERISM; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFECT; HUMAN; METABOLISM;

ALLOSTERIC REGULATION; CENTRAL NERVOUS SYSTEM DISEASES; EXCITATORY AMINO ACID AGENTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 79953077013     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16032097     Document Type: Article

References (56)

1. Conn, P.J.; Pin, J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237. (Pubitemid 27238875)
2. Coutinho, V.; Knopfel, T. Metabotropic glutamate receptors: Electrical and chemical signaling properties. Neuroscientist 2002, 8, 551-561. (Pubitemid 35379450)
3. Hermans, E.; Challiss, R.A. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: Prototypic family C G-protein-coupled receptors. Biochem. J. 2001, 359, 465-484. (Pubitemid 33063371)
4. Dhami, G.K.; Ferguson, S.S. Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol. Ther. 2006, 111, 260-271. (Pubitemid 43765534)
5. Niswender, C.M.; Conn, P.J. Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322.
6. Abe, T.; Sugihara, H.; Nawa, H.; Shigemoto, R.; Mizuno, N.; Nakanishi, S. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem. 1992, 267, 13361-13368.
7. Shigemoto, R.; Nomura, S.; Ohishi, H.; Sugihara, H.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 1993, 163, 53-57. (Pubitemid 23349393)
8. Romano, C.; Sesma, M.A.; McDonald, C.T.; O'Malley, K.; Van den Pol, A.N.; Olney, J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 1995, 355, 455-469.
9. Mudo, G.; Trovato-Salinaro, A.; Caniglia, G.; Cheng, Q.; Condorelli, D.F. Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain. Brain Res. 2007, 1149, 1-13. (Pubitemid 46659884)
10. Aronica, E.; Gorter, J.A.; Ijlst-Keizers, H.; Rozemuller, A.J.; Yankaya, B.; Leenstra, S.; Troost, D. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins. Eur. J. Neurosci. 2003, 17, 2106-2018.
11. Schools, G.P.; Kimelberg, H.K. mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats. J. Neurosci. Res. 1999, 58, 533-543. (Pubitemid 29530436)
12. Perroy, J.; Raynaud, F.; Homburger, V.; Rousset, M.C.; Telley, L.; Bockaert, J.; Fagni, L. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J. Biol. Chem. 2008, 283, 6799-6805.
13. Attucci, S.; Carla, V.; Mannaioni, G.; Moroni, F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol. 2001, 132, 799-806. (Pubitemid 32193636)
14. Awad, H.; Hubert, G.W.; Smith, Y.; Levey, A.I.; Conn, P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20, 7871-7879.
15. Doherty, A.J.; Palmer, M.J.; Henley, J.M.; Collingridge, G.L.; Jane, D.E. (RS)-2-chloro-5- hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 1997, 36, 265-267. (Pubitemid 27149516)
16. Pisani, A.; Gubellini, P.; Bonsi, P.; Conquet, F.; Picconi, B.; Centonze, D.; Bernardi, G.; Calabresi, P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106, 579-587. (Pubitemid 32925246)
17. Ugolini, A.; Corsi, M.; Bordi, F. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999, 38, 1569-1576. (Pubitemid 29457738)
18. Rosenbrock, H.; Kramer, G.; Hobson, S.; Koros, E.; Grundl, M.; Grauert, M.; Reymann, K.G.; Schroder, U.H. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 2010, 639, 40-46.
19. Chen, Y.; Conn, P.J. mGluR5 positive allosteric modulators. Drugs Fut. 2008, 33, 355-360.
20. Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8, 41-54.
21. Conn, P.J.; Lindsley, C.W.; Jones, C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30, 25-31.
22. Gregory, K.J.; Dong, E.N.; Meiler, J.; Conn, P.J. Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential. Neuropharmacology 2011, 60, 66-81.
23. Krystal, J.H.; Mathew, S.J.; D'Souza, D.C.; Garakani, A.; Gunduz-Bruce, H.; Charney, D.S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24, 669-693.
24. Ritzen, A.; Mathiesen, J.M.; Thomsen, C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol. 2005, 97, 202-213. (Pubitemid 41435091)
25. Ayala, J.E.; Chen, Y.; Banko, J.L.; Sheffler, D.J.; Williams, R.; Telk, A.N.; Watson, N.L.; Xiang, Z.; Zhang, Y.; Jones, P.J.; Lindsley, C.W.; Olive, M.F.; Conn, P.J. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34, 2057-2071.
26. Balschun, D.; Zuschratter, W.; Wetzel, W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006, 142, 691-702. (Pubitemid 44485913)
27. Uslaner, J.M.; Parmentier-Batteur, S.; Flick, R.B.; Surles, N.O.; Lam, J.S.; McNaughton C.H.; Jacobson M.A.; Hutson P.H. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 2009, 57, 531-538.
28. Cleva, R.M.; Hicks, M.P.; Gass, J.T.; Wischerath, K.C.; Plasters, E.T.; Widholm, J.J.; Olive, M.F. mGluR5 positive allosteric modulation enhances extinction learning following cocaine selfadministration. Behav. Neurosci. 2011, 125, 10-19.
29. Stefani, M.R.; Moghaddam, B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 2010, 639, 26-32.
30. Vardigan, J.D.; Huszar, S.L.; McNaughton, C.H.; Hutson, P.H.; Uslaner, J.M. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophreniaγ Pharmacol. Biochem. Behav. 2010, 95, 223-229.
31. Darrah, J.M.; Stefani, M.R.; Moghaddam, B. Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol. 2008, 19, 225-234. (Pubitemid 351670403)
32. Marino, M.J.; Conn, P.J. Direct and indirect modulation of the N-methyl D-aspartate receptor: Potential for the development of novel antipsychotic therapies. Curr. Drug Targets CNS Neurol. Disord. 2002, 1, 1-16.
33. Marino, M.J.; Conn, P.J. Glutamate-based therapeutic approaches: Allosteric modulators of metabotropic glutamate receptors. Curr. Opin. Pharmacol. 2006, 6, 98-102. (Pubitemid 43103825)
34. Conn, P.J.; Tamminga, C.; Schoepp, D.D.; Lindsley C. Schizophrenia: Moving beyond monoamine antagonists. Mol. Interv. 2008, 8, 99-107. (Pubitemid 351549907)
35. O'Brien, J.A.; Lemaire, W.; Chen, T.B.; Chang, R.S.; Jacobson, M.A.; Ha, S.N.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; Pettibone, D.J.; Conn, P.J.; Williams, D.L., Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 2003, 64, 731-740. (Pubitemid 37048578)
36. O'Brien, J.A.; Lemaire, W.; Wittmann, M.; Jacobson, M.A.; Ha, S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J.; Rowe, B.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J. Pharmacol. Exp. Ther. 2004, 309, 568-577. (Pubitemid 38542609)
37. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O'Brien, J A.; Lemaire, W.; Williams, D.L., Jr.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Duggan, M.E.; Hartman, G.D.; Conn, P.J.; Huff, J.R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 2004, 47, 5825-5828. (Pubitemid 39507327)
38. Kinney, G.G.; O'Brien, J.A.; Lemaire, W.; Burno, M.; Bickel, D.J.; Clements, M.K.; Chen, T.B.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, P.J.; Williams, D.L., Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 2005, 313, 199-206. (Pubitemid 40411343)
39. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P.J.; Wantuch, C.; Popiolek, M.; Day, M.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Gilbert, A.; Lai, M.; Pausch, M.H.; Pruthi, F.; Pulicicchio, C.; Brandon, N.J.; Comery, T.A.; Beyer, C.E.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K.L. ADX47273: A novel metabotropic glutamate receptor 5 selective positive allosteric modulator with preclinical antipsychotic-like and pro-cognitive activities. J. Pharmacol. Exp. Ther. 2008, 327, 827-839.
40. Chen, Y.; Nong, Y.; Goudet, C.; Hemstapat, K.; de Paulis, T.; Pin, J.P.; Conn, J. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 2007, 71, 1389-1398. (Pubitemid 46661543)
41. Engers, D.W.; Rodriguez, A.L.; Williams, R.; Hammond, A.S.; Venable, D.; Oluwatola, O.; Sulikowski, G.A.; Conn, P.J.; Lindsley, C.W. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem 2009, 4, 505-511.
42. Sharma, S.; Kedrowski, J.; Rook, J.M.; Smith, R.L.; Jones, C.K.; Rodriguez, A.L.; Conn, P.J.; Lindsley, C.W. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. J. Med. Chem. 2009, 52, 4103-4106.
43. Rodriguez, A.L.; Grier, M.D.; Jones, C.K.; Herman, E.J.; Kane, A.S.; Smith, R.L.; Williams, R.; Zhou, Y.; Marlo, J.E.; Days, E.L.; Blatt, T.N.; Jadhav, S.; Menon, U.N.; Vinson, P.N.; Rook, J.M.; Stauffer, S.R.; Niswender, C.M.; Lindsley, C.W.; Weaver, C.D.; Conn, P.J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 2010, 78, 1105-1123.
44. Rodriguez, A.L.; Nong, Y.; Sekaran, N.K.; Alagille, D.; Tamagnan, G.D.; Conn, P.J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 2005, 68, 1793-1802. (Pubitemid 41654362)
45. Chen, Y.; Goudet, C.; Pin, J.P.; Conn, P.J. N-{4-Chloro-2-[(1,3-dioxo-1, 3-dihydro-2H-isoindol-2- yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 2008, 73, 909-918. (Pubitemid 351397895)
46. Zhang, Y.; Rodriguez, A.L.; Conn, P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 2005, 315, 1212-1219. (Pubitemid 41635410)
47. Hammond, A.S.; Rodriguez, A.L.; Townsend, S.D.; Niswender, C.M.; Gregory, K.J.; Lindsley, C.W.; Conn, P.J. Discovery of a novel chemical class of mGlu5 allosteric ligands with distinct modes of pharmacology. ACS Chem. Neurosci. 2010, 1, 702-716.
48. Parmentier-Batteur, S.; Obrien, J.A.; Doran, S.; Nguyen, S.J.; Flick, R.B.; Uslaner, J.M.; Chen, H.; Finger, E.N.; Williams, T.M.; Jacobson, M.A.; Hutson, P.H. Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration. Neuropharmacology 2011, in press.
49. Fowler, S.W.; Ramsey, A.K.; Walker, J.M.; Serfozo, P.; Olive, M.F.; Schachtman, T.R.; Simonyi, A. Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats. Neurobiol. Learn Mem. 2011, 95, 73-79.
50. Homayoun, H.; Moghaddam, B. Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc. Natl. Acad. Sci. USA 2008,105, 18041-18066.
51. Homayoun, H.; Moghaddam, B. Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition. Eur. J. Pharmacol. 2010, 639, 33-39.
52. Lecourtier, L.; Homayoun, H.; Tamagnan, G.; Moghaddam, B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol. Psychiatry 2007, 62, 739-746. (Pubitemid 47374648)
53. Olive, M.F. Metabotropic glutamate receptor ligands as potential therapeutics for drug addiction. Curr. Drug Abuse Rev. 2009, 2, 83-98.
54. Olive, M.F. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur. J. Pharmacol. 2010, 639, 47-58.
55. Gass, J.T.; Olive, M.F. Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol. Psychiatry 2009, 65, 717-720.
56. Reichel, C.M.; Schwendt, M.; McGinty, J.F.; Olive, M.F.; See, R.E. Loss of object recognition memory produced by exteded access to methamphetamine self-admistration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 2011, 36, 782-792.